Cost-effectiveness analysis comparing chemotherapy regimens in the treatment of AIDS-related Kaposi's sarcoma in Brazil.

@article{Vanni2006CosteffectivenessAC,
  title={Cost-effectiveness analysis comparing chemotherapy regimens in the treatment of AIDS-related Kaposi's sarcoma in Brazil.},
  author={Tazio Vanni and Benedito Ant{\^o}nio Lopes da Fonseca and Car{\'i}si Anne Polanczyk},
  journal={HIV clinical trials},
  year={2006},
  volume={7 4},
  pages={194-202}
}
BACKGROUND Economic analyses of agents used in the treatment of AIDS and opportunistic diseases are particularly important in developing countries. PURPOSE To analyze the cost-effectiveness of AIDS-related Kaposi's sarcoma (AIDS-KS) chemotherapy regimens in Brazil. METHOD A decision-analysis model was developed, and effectiveness data were derived from randomized phase III trials evaluating pegylated liposomal doxorubicin (PLD), liposomal daunorubicin (DNX), and the ABV regimen (doxorubicin… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Cost - effectiveness analysis comparing chemotherapy regimens in the treatment of AIDS - related Kaposi 's sarcoma in Brazil . BACKGROUND .
To analyze the cost - effectiveness of AIDS - related Kaposi 's sarcoma ( AIDS - KS ) chemotherapy regimens in Brazil .
To analyze the cost - effectiveness of AIDS - related Kaposi 's sarcoma ( AIDS - KS ) chemotherapy regimens in Brazil .
A decision - analysis model was developed , and effectiveness data were derived from randomized phase III trials evaluating pegylated liposomal doxorubicin ( PLD ) , liposomal daunorubicin ( DNX ) , and the ABV regimen ( doxorubicin , bleomycin , and vincristine ) .
BleomycinIs component of chemotherapy regimenbleomycin/doxorubicin/vinblastine protocol
A decision - analysis model was developed , and effectiveness data were derived from randomized phase III trials evaluating pegylated liposomal doxorubicin ( PLD ) , liposomal daunorubicin ( DNX ) , and the ABV regimen ( doxorubicin , bleomycin , and vincristine ) .
A decision - analysis model was developed , and effectiveness data were derived from randomized phase III trials evaluating pegylated liposomal doxorubicin ( PLD ) , liposomal daunorubicin ( DNX ) , and the ABV regimen ( doxorubicin , bleomycin , and vincristine ) .
BleomycinIs component of chemotherapy regimenABV Regimen
A decision - analysis model was developed , and effectiveness data were derived from randomized phase III trials evaluating pegylated liposomal doxorubicin ( PLD ) , liposomal daunorubicin ( DNX ) , and the ABV regimen ( doxorubicin , bleomycin , and vincristine ) .
A decision - analysis model was developed , and effectiveness data were derived from randomized phase III trials evaluating pegylated liposomal doxorubicin ( PLD ) , liposomal daunorubicin ( DNX ) , and the ABV regimen ( doxorubicin , bleomycin , and vincristine ) .
A decision - analysis model was developed , and effectiveness data were derived from randomized phase III trials evaluating pegylated liposomal doxorubicin ( PLD ) , liposomal daunorubicin ( DNX ) , and the ABV regimen ( doxorubicin , bleomycin , and vincristine ) .
A decision - analysis model was developed , and effectiveness data were derived from randomized phase III trials evaluating pegylated liposomal doxorubicin ( PLD ) , liposomal daunorubicin ( DNX ) , and the ABV regimen ( doxorubicin , bleomycin , and vincristine ) .
DoxorubicinIs component of chemotherapy regimenbleomycin/doxorubicin/vinblastine protocol
A decision - analysis model was developed , and effectiveness data were derived from randomized phase III trials evaluating pegylated liposomal doxorubicin ( PLD ) , liposomal daunorubicin ( DNX ) , and the ABV regimen ( doxorubicin , bleomycin , and vincristine ) .
A decision - analysis model was developed , and effectiveness data were derived from randomized phase III trials evaluating pegylated liposomal doxorubicin ( PLD ) , liposomal daunorubicin ( DNX ) , and the ABV regimen ( doxorubicin , bleomycin , and vincristine ) .
A decision - analysis model was developed , and effectiveness data were derived from randomized phase III trials evaluating pegylated liposomal doxorubicin ( PLD ) , liposomal daunorubicin ( DNX ) , and the ABV regimen ( doxorubicin , bleomycin , and vincristine ) .
DoxorubicinIs component of chemotherapy regimenABV Regimen
A decision - analysis model was developed , and effectiveness data were derived from randomized phase III trials evaluating pegylated liposomal doxorubicin ( PLD ) , liposomal daunorubicin ( DNX ) , and the ABV regimen ( doxorubicin , bleomycin , and vincristine ) .
A decision - analysis model was developed , and effectiveness data were derived from randomized phase III trials evaluating pegylated liposomal doxorubicin ( PLD ) , liposomal daunorubicin ( DNX ) , and the ABV regimen ( doxorubicin , bleomycin , and vincristine ) .
A decision - analysis model was developed , and effectiveness data were derived from randomized phase III trials evaluating pegylated liposomal doxorubicin ( PLD ) , liposomal daunorubicin ( DNX ) , and the ABV regimen ( doxorubicin , bleomycin , and vincristine ) .
Cost - effectiveness analysis comparing chemotherapy regimens in the treatment of AIDS - related Kaposi 's sarcoma in Brazil . BACKGROUND .
To analyze the cost - effectiveness of AIDS - related Kaposi 's sarcoma ( AIDS - KS ) chemotherapy regimens in Brazil .
To analyze the cost - effectiveness of AIDS - related Kaposi 's sarcoma ( AIDS - KS ) chemotherapy regimens in Brazil .
To analyze the cost - effectiveness of AIDS - related Kaposi 's sarcoma ( AIDS - KS ) chemotherapy regimens in Brazil .
To analyze the cost - effectiveness of AIDS - related Kaposi 's sarcoma ( AIDS - KS ) chemotherapy regimens in Brazil .
All Topics